Oncogenes

Affimed Announces Publication of Comprehensive Preclinical Data Demonstrating the Therapeutic Potential of AFM24 in EGFR-expressing Tumors

Retrieved on: 
Friday, July 30, 2021
Organic compounds, Epidermal growth factor receptor, Oncogenes, KRAS, Chemical compounds, Quinazolines, Cancer, Amines, Chloroarenes, Gefitinib, Icotinib

Preclinical data demonstrate AFM24s activation of the innate immune system, acting independently of EGFR-expression levels, EGFR-pathway mutations and downstream signal transduction.

Key Points: 
  • Preclinical data demonstrate AFM24s activation of the innate immune system, acting independently of EGFR-expression levels, EGFR-pathway mutations and downstream signal transduction.
  • The published data supported the Investigational New Drug application for the ongoing AFM24 Phase 1/2a dose escalation study.
  • The published data were the basis for the Investigational New Drug (IND) clearance for Affimeds ongoing Phase 1/2a study with AFM24 monotherapy in patients with EGFR expressing solid tumors.
  • AFM24 is effective against many EGFR-positivetumorcells, regardless of EGFR expression level and KRAS/BRAF mutational status within in vitro studies.

Global EGFR Tests (In Vitro Diagnostics) Market Analysis and Forecast Model 2021 with COVID-19 Market Impact - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 20, 2021
Health, General Health, Branches of biology, Laboratory techniques, Biology, Epidermal growth factor receptor, Oncogenes, Immunohistochemistry, EGFR, In vitro

The "EGFR Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 Market Impact)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "EGFR Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 Market Impact)" report has been added to ResearchAndMarkets.com's offering.
  • EGFR Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 Market Impact) is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.
  • The model discusses in detail the impact of COVID-19 on EGFR Tests market for the year 2020 and beyond.
  • The model includes EGFR Immunohistochemistry Tests, EGFR Sanger Sequencing Tests, EGFR Nucleic Acid Amplification Tests (NAATs), and EGFR Other Tests (EGFR ISH and Mass Array tests).

Preventing lung cancer's unwelcome return

Retrieved on: 
Tuesday, July 13, 2021
Branches of biology, Cancer, Clinical medicine, Lung cancer, Oncology, Epidermal growth factor receptor, Oncogenes, Non-small-cell lung carcinoma, Brachyury, Neoplasm, KRAS, Somatic evolution in cancer

Cold Spring Harbor Laboratory (CSHL) Visiting Scientist Raffaella Sordella investigated a similar problem that occurs in some lung cancers .

Key Points: 
  • Cold Spring Harbor Laboratory (CSHL) Visiting Scientist Raffaella Sordella investigated a similar problem that occurs in some lung cancers .
  • Approximately 15% of non-small cell lung cancers have a mutation in a growth receptor called EGFR, causing tumor cells to grow uncontrollably.
  • Researchers developed an effective drug that inhibits EGFR and kills cancer cells, but the tumor grows back later.
  • Understanding how resistance arises in lung cancer is key to figuring out how to eliminate a tumor.

May River Capital Formalizes Executive Resource Group; Announces Partnership with P&L Leader Rahul Deshmukh

Retrieved on: 
Tuesday, June 29, 2021
Finance, Money, Economy, ERG, Oncogenes, Private equity

CHICAGO, June 29, 2021 /PRNewswire/ --Chicago-based private equity firm, May River Capital announced today that it has formed May River ERG, LLC ("May River ERG"), an affiliate of May River's management company, May River Capital, LLC.

Key Points: 
  • CHICAGO, June 29, 2021 /PRNewswire/ --Chicago-based private equity firm, May River Capital announced today that it has formed May River ERG, LLC ("May River ERG"), an affiliate of May River's management company, May River Capital, LLC.
  • The new affiliate will comprise certain members of May River's Executive Resource Group, its operating partner network.
  • Deshmukh has nearly 30 years of leadership experience within a broad range of global industries.
  • "I am excited to partner with May River Capital in the development of a new engineered products and instrumentation platform," said Deshmukh.

Anji to Advance MCL1 Inhibitor Program from Broad Institute into Clinical Trials

Retrieved on: 
Thursday, June 17, 2021
Research, Hospitals, Clinical trials, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, Branches of biology, Membrane proteins, Proteins, Programmed cell death, Apoptosis, Oncogenes, Bcl-2 family, MCL1, Bcl-2

Anji Pharma (Anji), a global pharmaceutical company focused on tackling high-value drug targets validated by human genetics, announced that an Anji subsidiary has acquired worldwide development and commercialization rights to an MCL1 inhibitor program through a license from the Broad Institute of MIT and Harvard and will work to advance the programs MCL1 inhibitors through clinical development.

Key Points: 
  • Anji Pharma (Anji), a global pharmaceutical company focused on tackling high-value drug targets validated by human genetics, announced that an Anji subsidiary has acquired worldwide development and commercialization rights to an MCL1 inhibitor program through a license from the Broad Institute of MIT and Harvard and will work to advance the programs MCL1 inhibitors through clinical development.
  • MCL1 is a member of the Bcl-2 family, normally acting as a brake on the apoptosis pathway.
  • In many human cancers, the Mcl-1 gene is highly amplified, shifting the balance from pro- to anti-apoptotic signals and promoting cancer cell survival and tumor formation.
  • The MCL1 program is one of several programs pursued by the Center for Development of Therapeutics (CDoT) at the Broad Institute.

Autolus Therapeutics Announces Innovation Licensing and Access Pathway (ILAP) designation for obe-cel for the treatment of relapsed/refractory adult B-cell ALL

Retrieved on: 
Tuesday, June 15, 2021
Treatment of cancer, Oncogenes, Oncolytics Biotech

(RELATED: MHRA sheds light on pathway to accelerate R&D ,Regulatory Focus24 December 2020).

Key Points: 
  • (RELATED: MHRA sheds light on pathway to accelerate R&D ,Regulatory Focus24 December 2020).
  • Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer.
  • Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors.
  • In collaboration with our academic partner, UCL, obe-cel is currently being evaluated in a Phase 1 clinical trial in adult ALL and B-NHL.

Revolution Medicines to Host Science Talk Webcast Highlighting Learnings from Recent Preclinical and Clinical Studies of RAS Inhibitors

Retrieved on: 
Thursday, June 10, 2021
Oncogenes, Ras GTPase, Cancer, Oncology, Branches of biology, Targeted therapy, Clinical medicine, Medicine

REDWOOD CITY, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today announced that it will host a Science Talk webcast to highlight learnings from recent preclinical and clinical studies of RAS inhibitors.

Key Points: 
  • REDWOOD CITY, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier targets in RAS-addicted cancers, today announced that it will host a Science Talk webcast to highlight learnings from recent preclinical and clinical studies of RAS inhibitors.
  • Emerging Insights about RAS-Addicted Cancers, Drug Resistance and Treatment Strategies
    To participate in the live webcast, please visit the Events & Presentations page of Revolution Medicines website at https://ir.revmed.com/events-and-presentations .
  • Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit high-value frontier targets in RAS-addicted cancers.
  • The companys R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies.

C4 Therapeutics Presents Pre-clinical Data on CFT8919, A Selective Degrader of EGFR L858R, at Keystone Symposium on Targeted Protein Degradation

Retrieved on: 
Monday, June 7, 2021
Tyrosine kinase receptors, Oncogenes, Epidermal growth factor receptor, EGFR

We are excited to share strong preclinical data that establishes CFT8919 as a potent and selective degrader of EGFR L858R, a mutation responsible for more than a third of mutant EGFR lung cancer diagnoses.

Key Points: 
  • We are excited to share strong preclinical data that establishes CFT8919 as a potent and selective degrader of EGFR L858R, a mutation responsible for more than a third of mutant EGFR lung cancer diagnoses.
  • Across our portfolio, we see the potential for targeted protein degradation to transform patient care.
  • CFT8919 does not induce degradation of known cereblon neo-substrates SALL4 or GSPT1, indicating that the potential associated toxicities will not be liabilities.
  • Additionally, in vivo data demonstrates the following:
    CFT8919 degrades and inhibits mutant EGFR in tumors upon oral administration.

Cullinan Oncology Announces Phase 1/2a Interim Data For Cullinan Pearl’s CLN-081 in NSCLC EGFR Exon 20 Patients

Retrieved on: 
Friday, June 4, 2021
Lung cancer, Tyrosine kinase receptors, Epidermal growth factor receptor, Oncogenes, Non-small-cell lung carcinoma, Quinazolines, Organic compounds, Cancer, Branches of biology, Chloroarenes

CLN-081 is an orally available, irreversible EGFR inhibitor, utilizing a unique pyrrolopyrimidine scaffold that was designed to selectively target cells expressing mutant EGFR variants, including exon 20, while sparing cells expressing wild type (WT) EGFR.

Key Points: 
  • CLN-081 is an orally available, irreversible EGFR inhibitor, utilizing a unique pyrrolopyrimidine scaffold that was designed to selectively target cells expressing mutant EGFR variants, including exon 20, while sparing cells expressing wild type (WT) EGFR.
  • The current analysis of the ongoing trial evaluated a total of 45 NSCLC patients with EGFR exon 20 insertion mutations who received at least one dose of CLN-081 as of the April 1, 2021, data cutoff, and were evaluable for safety.
  • As of the data cutoff, 42 of 45 patients were response evaluable across all dose cohorts tested.
  • Cullinan is evaluating various doses of CLN-081 in a Phase 1/2a trial in patients with NSCLC harboring Ins20 mutations that have progressed post chemotherapy.

Vincerx Pharma Presents Clinical Data on VIP512, its PTEFb/CDK9 Inhibitor, in Patients with Double-Hit Lymphoma at ASCO 2021

Retrieved on: 
Friday, June 4, 2021
Branches of biology, Oncogenes, Non-Hodgkin lymphoma, Bcl-2, Programmed cell death, Myc

VIP152, a potent and selective inhibitor of CDK9, has completed dose escalation in patients with advanced malignancies (NCT02635672).

Key Points: 
  • VIP152, a potent and selective inhibitor of CDK9, has completed dose escalation in patients with advanced malignancies (NCT02635672).
  • DHL is defined as a dual arrangement or overexpression of the MYC gene and either the B-cell lymphoma 2 (BCL2) or BCL6 genes.
  • Four patients had 2 prior lines of therapy and 3 patients had 3 prior lines of therapy.
  • Forward-looking statements speak only as of the date hereof, and Vincerx disclaims any obligation to update any forward-looking statements.